Skip to main content
Premium Trial:

Request an Annual Quote

World Fusion, Lumenogix to Integrate Technologies to Enable NGS-based Drug Discovery

NEW YORK (GenomeWeb) – World Fusion and Lumenogix today announced a strategic partnership to integrate their technologies.

World Fusion will integrate its Life Sciences Knowledge Bank for accelerating drug discovery with Lumenogix's Bioinformatics-in-a-Box for next-generation sequencing data analysis. The new system will link NGS-processed results managed by Lumenogix's technology with small molecule and protein data managed by LSKB, enabling pharma to take advantage of the opportunities offered by NGS technology, the partners said.

Financial and other terms of the deal were not disclosed.

"World Fusion offers us an opportunity to deliver chemical, gene, protein, and disease information to our clients," Lumenogix CEO Boris Umylny said in a statement. "Together with World Fusion we will deliver a complete solution to the pharmaceutical industry and help them solve the data mining challenges inherent in high-throughput sequencing data."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more